{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T12:19:56Z","timestamp":1794917996416,"version":"4.9.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,23]]},"DOI":"10.7759\/cureus.97588","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T02:33:06Z","timestamp":1763951586000},"source":"Crossref","is-referenced-by-count":3,"title":["Cardiovascular Outcomes and Hyperkalemia Risk in Patients With Diabetes, Chronic Kidney Disease and Heart Failure: A Real-World Comparison of Non-steroidal versus Steroidal Mineralocorticoid Receptor Antagonists"],"prefix":"10.7759","author":[{"given":"Ayoyimika O","family":"Okunlola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olayinka","family":"Kolawole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Otabor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulraheem","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laith","family":"Alomari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abiodun B","family":"Idowu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.124.011629","article-title":"Mineralocorticoid receptor antagonists in heart failure: an update","volume":"17","author":"Ferreira JP","year":"2024","unstructured":"Ferreira JP, Pitt B, Zannad F. Mineralocorticoid receptor antagonists in heart failure: an update. Circ Heart Fail. 2024, 17:e011629. 10.1161\/CIRCHEARTFAILURE.124.011629","journal-title":"Circ Heart Fail"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.03.426","article-title":"Mineralocorticoid receptor antagonists in patients with heart failure and impaired renal function","volume":"83","author":"Matsumoto S","year":"2024","unstructured":"Matsumoto S, Henderson AD, Shen L, et al.. Mineralocorticoid receptor antagonists in patients with heart failure and impaired renal function. J Am Coll Cardiol. 2024, 83:2426-36. 10.1016\/j.jacc.2024.03.426","journal-title":"J Am Coll Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/kidneydial2020019","article-title":"Role of mineralocorticoid receptor antagonists in diabetic kidney disease","volume":"8","author":"Alexandrou ME","year":"2022","unstructured":"Alexandrou ME, Theodorakopoulou MP, Sarafidis PA. Role of mineralocorticoid receptor antagonists in diabetic kidney disease. Kidney Dial. 2022, 8:163-82. 10.3390\/kidneydial2020019","journal-title":"Kidney Dial"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.06.021","article-title":"Underutilization of mineralocorticoid antagonists in patients with heart\u00a0failure with\u00a0reduced\u00a0ejection fraction","volume":"82","author":"Matsumoto S","year":"2023","unstructured":"Matsumoto S, Kondo T, Jhund PS, et al.. Underutilization of mineralocorticoid antagonists in patients with heart\u00a0failure with\u00a0reduced\u00a0ejection fraction. J Am Coll Cardiol. 2023, 82:1080-91. 10.1016\/j.jacc.2023.06.021","journal-title":"J Am Coll Cardiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal R","year":"2021","unstructured":"Agarwal R, Kolkhof P, Bakris G, Bauersachs J, Haller H, Wada T, Zannad F. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021, 42:152-61. 10.1093\/eurheartj\/ehaa736","journal-title":"Eur Heart J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2024.2316572","article-title":"Non-steroidal mineralocorticoid antagonists and hyperkalemia monitoring in chronic kidney disease patients associated with type II diabetes: a narrative review","volume":"136","author":"Morales J","year":"2024","unstructured":"Morales J, Palmer BF. Non-steroidal mineralocorticoid antagonists and hyperkalemia monitoring in chronic kidney disease patients associated with type II diabetes: a narrative review. Postgrad Med. 2024, 136:111-9. 10.1080\/00325481.2024.2316572","journal-title":"Postgrad Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13071693","article-title":"Current application of mineralocorticoid antagonist (MRA) in heart failure and CKD: does non-steroidal drug add novel insights","volume":"13","author":"Carlino I","year":"2025","unstructured":"Carlino I, Pirrotta F, Gennari L, Palazzuoli A. Current application of mineralocorticoid antagonist (MRA) in heart failure and CKD: does non-steroidal drug add novel insights. Biomedicines. 2025, 13:1693. 10.3390\/biomedicines13071693","journal-title":"Biomedicines"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2469","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial","volume":"24","author":"Filippatos G","year":"2022","unstructured":"Filippatos G, Pitt B, Agarwal R, et al.. Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial. Eur J Heart Fail. 2022, 24:996-1005. 10.1002\/ejhf.2469","journal-title":"Eur J Heart Fail"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.057983","article-title":"Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial","volume":"145","author":"Filippatos G","year":"2022","unstructured":"Filippatos G, Anker SD, Agarwal R, et al.. Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial. Circulation. 2022, 145:437-47. 10.1161\/CIRCULATIONAHA.121.057983","journal-title":"Circulation"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal R","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, et al.. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022, 43:474-84. 10.1093\/eurheartj\/ehab777","journal-title":"Eur Heart J"},{"key":"ref11","unstructured":"TriNetX. Real-world data network for clinical research. (2023). Accessed. April 18, 2025: https:\/\/trinetx.com\/."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S010","article-title":"10. Cardiovascular disease and risk management: standards of care in diabetes-2025","volume":"48","year":"2025","unstructured":"10. Cardiovascular disease and risk management. standards of care in diabetes-2025. Diabetes Care. 2025, 48:S207-38. 10.2337\/dc25-S010","journal-title":"Diabetes Care"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s12471-025-01967-y","article-title":"2023 European Society of Cardiology guidelines for the management of cardiovascular disease in patients with diabetes: statement of endorsement by the NVVC","volume":"33","author":"Martens FM","year":"2025","unstructured":"Martens FM, Visseren FL, Westerink J, et al.. 2023 European Society of Cardiology guidelines for the management of cardiovascular disease in patients with diabetes: statement of endorsement by the NVVC. Neth Heart J. 2025, 33:216-25. 10.1007\/s12471-025-01967-y","journal-title":"Neth Heart J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/415709-cardiovascular-outcomes-and-hyperkalemia-risk-in-patients-with-diabetes-chronic-kidney-disease-and-heart-failure-a-real-world-comparison-of-non-steroidal-versus-steroidal-mineralocorticoid-receptor-antagonists","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T02:33:07Z","timestamp":1763951587000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/415709-cardiovascular-outcomes-and-hyperkalemia-risk-in-patients-with-diabetes-chronic-kidney-disease-and-heart-failure-a-real-world-comparison-of-non-steroidal-versus-steroidal-mineralocorticoid-receptor-antagonists"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,23]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.97588","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,23]]}}}